

Syngene

Putting Science to Work


Integrating Multiple Data using
Syngene's Virtual Liver

Quality
Confidentiality
Innovation
Science



- Use microarray results as input to the virtual liver model for prediction of toxicity
- Combine multiple experimental information for toxicity prediction

Flow Chart of Data Handling



Gene sets used for GSEA analysis

Insulin signalling

Glycolysis

Glycogen synthesis

Glycogen depletion

Gluconeogenesis

TCA cycle

Oxidative phosphorylation

ROS pathway

ROS pathway (Broad)

Lipogenesis

Fatty acid transport and activation

Triglyceride synthesis

Beta-oxidation

Ketone body synthesis

Phospholipid synthesis

VLDL assembly and secretion

Cholesterol synthesis

Bile acid synthesis

Canalicular bile transport

Sinusoidal bile transport

Cytoskeleton network

Apoptosis

Inflammation (Kegg)

Aspartate-glutamate network (Kegg)

Cysteine-methionine network (Kegg)

Unfolded protein response (Reactome)

Ubiquitin mediated proteolysis

GSH depletion by conjugation

GSH depletion by enzyme inhibition

Phase 1 drug metabolism enzymes

Phase 2 drug metabolism enzymes

- Down regulation of mRNA (Direct Effect)
 - Gene product is inhibited due to transcriptional inhibition of a master regulator
- Up regulation of mRNA (Indirect Effect)
 - Activity of an enzyme is inhibited due to the drug. Synthesis of either the same enzyme or another increases in compensation
 - e.g. increased glucose concentration in plasma can up-regulate GLUT 2 to increase the entry of glucose in liver
 - e.g. Valproate treatment is known to inhibit beta oxidation and gluconeogenesis. Increase in mRNA of the relevant enzymes are observed

- Experimental details:
 - 350 mg/kg/day
 - Frequency of dosing: daily, Oral gavage
 - Animals were sacrificed and samples are collected at day 1, day 3 and day 5
 - Sample are analysed using Agilent 2100 BioAnalyzer
 - GEO dataset : GSE8858

List of affected biological processes by cyclosporine treatment





Processes	1 day	3 days	5 days
Glycolysis	Down	Down*	Up
Betaoxidation	Up	Down*	Down*
Canalicular bile transporters	Down	Up	Down*
Sinusoidal bile transporters	Up	Up*	Up
Cytoskeleton network	Down	Down	Up*
ROS synthesis	Up	Up	Up*
Lipogenesis	Down	Down*	Down


- Each process change is represented by a set a parameters in the model
- The altered parameters are input into the model and simulations performed
- The results of the simulations are analyzed

Parameterset - Values	
...ACL	Time series Cyclos...
...PFK	Time Series Cyclos...
...Time series for ACC	Time series Cylosp...
...FAS	Time Series Cyclos...
...CPT1	Time series_exten...
...GK_Vmax	Time Series Cyclos...
...H2O2prod_RO5	Time series Cyclos...
... Homeostasis : 13000.0	

Observation	Cause
TG accumulation	Increased β oxidation, <i>denovo</i> lipogenesis
Decreased Redox potential	Increased oxidative stress
Minor increase in blood TCA	Changed transporter activity
25% reduction in ATP	Reduced glycolytic activity

- Initially there is an inhibition of CPT1 (lowered β -oxidation)
- At later time points there is an increase in denovo-lipogeneis
- Both lead to TG accumulation







- To the microarray data, we added other experimental inputs to see whether this platform could “integrate” data from multiple sources
- For cyclosporine, we added two measurements
 - Membrane potential change in the presence of drug
 - BSEP inhibition by cyclosporine
- We then performed the simulations again to look at the effect on the predictions

Inputting Membrane potential allows a more realistic simulation of ATP effect

- The reduction in membrane potential causes an impact on the mitochondrial energy production
- This affects the overall energetics in the cell and reproduces the cyclosporine impact on ATP more realistically



- The synergistic impact of ATP reduction and BSEP suppression is able to predict cyclosporine cholestatic potential correctly
- Note that merely adding the BSEP inhibition effect does not capture this



Observation (Microarray alone, Microarray & other measurements)	Cause
TG accumulation	Increased β oxidation, denovo lipogenesis
Decreased Redox potential	Increased oxidative stress Increased oxidative stress due to mitochondrial dysfunction
Minor increase in blood bile salts	Changed transporter activity
Profound increase in blood bile salts	Synergistic Effects of transporter & energetics
25% reduction in ATP	Reduced glycolytic activity
40-50% reduction in cellular ATP	Impaired mitochondrial function leading to lowered oxidative phosphorylation



Thank you